Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
NEW YORK (Reuters Health) – A small study indicates that most patients with cutaneous B-cell lymphoma who respond well to rituximab relapse after about two years. On the…
NEW YORK (Reuters Health) – Contrary to a historically pessimistic outlook, high-risk prostate cancer can be controlled with moderate high-dose radiation treatment and prolonged androgen-deprivation therapy (ADT). That…
The Medicare program has different financial incentives. Under Medicare Fee-for-Service, patients are billed for each individual procedure they undergo. Under Medicare Advantage, patients have an annual fixed amount…
Adam Gazzaley, MD, PhD, Director, Neuroscience Imaging Center at UCSF Medical Center, explains how the immersive nature of video games can be used to benefit medical disorders as…
By Will Boggs, MD NEW YORK (Reuters Health) – Carboplatin plus pemetrexed improves survival over pemetrexed alone in ambulatory patients with advanced non-small-cell lung cancer (NSCLC), randomized trial…
Uncontrolled blood pressure can increase the risk for possible heart attack or stroke. In the U.S., almost half the patients with high blood pressure do not have it…
NEW YORK (Reuters Health) – An updated meta-analysis supports the strategy of giving intravesical chemotherapy (IVC) immediately after bladder tumor resection to reduce the risk of recurrence. “However,…
NEW YORK (Reuters Health) – The cumulative incidence of osteonecrosis of the jaw was about 2% over 6 years among women with early breast cancer who received intensive…
NEW YORK (Reuters Health) – Morbidity associated with inguinal lymphadenectomy in patients with penile carcinoma has declined, and is “reasonable” considering the potential benefit, a Brazilian team reports.…
By David Douglas NEW YORK (Reuters Health) – Dual HER2 blockade didn’t increase heart problems in a meta-analysis of data from patients with HER2-positive breast cancer. “The combination…
